Protheragen

Protheragen, a dedicated preclinical research service provider specializing in rare diseases, announces its comprehensive diagnostic development services aimed at empowering researchers in the realm of rare disease research and drug development.

Protheragen announced the release of its disease model development services provided to enhance rare disease research.

Rare diseases, also known as orphan diseases, affect a small percentage of the population, making them particularly challenging to diagnose and treat.

A pioneering shift in the research, diagnosis, and treatment of rare genetic diseases is on the horizon, powered by viral vector-based gene therapy.

In a pioneering effort to revolutionize life science research, a wide range of cost-effective animal disease models, from Drosophila to non-human primates, from knockout models to different disease models, are released.

In the pursuit of advancing disease research and its treatment, animal cognitive behavior is studied in a wide range of animal species.

In today's fast-paced and stressful society, the prevalence of anxiety and depression has become a significant concern. Emotion-related animal behavior tests aim to provide a good research tool for the study of emotion-associated diseases.

As several gene therapy approvals for rare disease treatment gain steam in 2023, a comprehensive set of gene therapy development solutions is released to pave richer avenues for rare disease research.